BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints PR Newswire SAN DIEGO...
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for...
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata” or...
Support
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads